Saving lives and reducing cost through the development of accessible and easy-to-use diagnostic tests.
‘Together with a strong international network of world leading academic and corporate partners, Qurin is developing a revolutionary, low threshold nanotechnology-based platform for (early) diagnosis, monitoring and personalized treatment of cancer and other medical conditions using urine as a liquid biopsy.’
Nanotechnology that changes the current health paradigm.
‘At Qurin Diagnostics we leverage the power of state-of-the-art nanotechnology through the development of a versatile diagnostic technology platform for noninvasive testing. Current developments are focused on advanced biochip technology suitable for multiple biological and biomedical applications.’
We bring together the expertise for nanotechnology-enabled diagnostics.
Combining world leading clinical and technological expertise enables us to develop revolutionary urine-based diagnostics. Qurin was founded as a result of a collaborative research program at the University of Twente and the VUmc Cancer Center Amsterdam under leadership of professors Bob Pinedo and Albert van den Berg. Expertise in oncology and nanotechnology was combined to lay the foundation of nanotechnology-enabled early cancer diagnostics based on the detection of biomarker signatures in urine. To accelerate these developments, Qurin initiates and invests in academic and industrial partnerships to improve and expand the capabilities and applications of our diagnostic technology platform.
GET IN TOUCH